DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
View / Open Files
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Ng, Aik Seng
Low, Zun Siong
Prasannan, Praseetha
Gong, Chun
Tan, Michelle Guet Khim
Nagarajan, Chandramouli
Huang, Dachuan
Lu, Pang Wan
Lim, Jing Quan
Barrans, Sharon
Ong, Choon Kiat
Lim, Soon Thye
Chng, Wee Joo
Follows, George
Du, Ming-Qing
Goh, Yeow Tee
Tan, Suat Hoon
Grigoropoulos, Nicholas Francis
Publication Date
2021-10-16Journal Title
Mol Cancer
ISSN
1476-4598
Publisher
Springer Science and Business Media LLC
Volume
20
Issue
1
Pages
134
Language
eng
Type
Article
This Version
VoR
Physical Medium
Electronic
Metadata
Show full item recordCitation
Kizhakeyil, A., Zaini, N. B. M., Poh, Z. S., Wong, B. H. S., Loh, X., Ng, A. S., Low, Z. S., et al. (2021). DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.. Mol Cancer, 20 (1), 134. https://doi.org/10.1186/s12943-021-01437-0
Abstract
Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma
(DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms
through which it occurs are incompletely understood
[1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still
evolve into aggressive forms resistant even to newer therapies [2].
Sponsorship
This research was supported, in part, by Start-Up Grant to NKV provided
by Lee Kong Chian School of Medicine, Nanyang Technological University
Singapore (L0412290), the Singapore Ministry of Education (MOE) under its
MOE Academic Research Fund (AcRF) Tier 2 Grant (MOE2017-T2–2-004), and
the National Research Foundation Singapore under its Open Fund Large
Collaborative Grant (OFLCG18May-0028) and administered by the Singapore
Ministry of Health’s National Medical Research Council (NMRC). N.F.G.
acknowledges funding support from the Singapore Ministry of Health’s
National Medical Research Council under its NMRC of Singapore Transition
Award (NMRC/TA/0051/2016), Kay Kendall Leukaemia Fund Junior Clinical
Research Training Fellowship (KKL649) and the Addenbrooke’s Charitable
Trust Research Training Fellowship. D.H. was supported by the Medical
Research Council (MR/M008584/1) and Blood Cancer UK and receives core
funding from Wellcome (203151/Z/16/Z) and MRC to the Wellcome-MRC
Cambridge Stem Cell Institute and from the CRUK Cambridge Centre
(A25117). A.K. and Z.S.P. were provided with PhD fellowship by Lee Kong
Chian School of Medicine, Nanyang Technological University Singapore.
B.H.S.W. was provided with PhD fellowship by HealthTech NTU, Nanyang
Technological University Singapore.
Funder references
Wellcome Trust (203151/Z/16/Z)
Medical Research Council (MR/M008584/1)
Cancer Research UK (A25117)
Identifiers
External DOI: https://doi.org/10.1186/s12943-021-01437-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329796
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.